ADVATE is a medicine used to replace clotting factor (factor VIII or antihemophilic factor) that is missing in people with hemophilia A (also called “classic” hemophilia). ADVATE is used to prevent and control bleeding in adults and children (0-16 years) with hemophilia A. Your healthcare provider (HCP) may give you ADVATE when you have surgery. ADVATE can reduce the number of bleeding episodes in adults and children (0-16 years) when used regularly (prophylaxis). ADVATE is not used to treat von Willebrand disease.

What is ADVATE® [Antihemophilic Factor (Recombinant)]?

In the hemophilia A community, no two patients are the same

When finding a treatment for hemophilia A, you and your healthcare provider should consider your individual needs.¹ There are many characteristics that make you unique.^1,2

Each patient with hemophilia A is unique and has different needs, lifestyle, bleed frequency, personal goals – ADVATE [Antihemophilic Factor (Recombinant)] is a treatment option for hemophilia A.

While living with hemophilia A will always be a part of your reality—both the welcome and unwelcome moments—you need treatment options that can help navigate the complexities of real life with hemophilia A.

What is a bleeding phenotype?

A patient’s bleeding phenotype is a collection of his or her bleed history, including bleeding disorder type and severity, annual bleed frequency, and overall joint health.³

What is PK?

Pharmacokinetics (or “PK”) is the science of how a drug is used up in the body.⁴ A person's PK profile helps determine how quickly or slowly his or her body breaks down treatment. Each person’s PK profile is different, and treatment can be personalized to your profile.⁵

About ADVATE

For adults and children with hemophilia A, ADVATE temporarily replaces the clotting factor VIII that's missing or low in the blood.^6,7 In 2003, ADVATE became the first recombinant factor VIII treatment free of blood-based additives.^7,8

What does recombinant mean?

Today, clotting factor VIII concentrates can be made without human plasma. These types of infusions are called recombinant clotting factors. Recombinant factor VIII was one of the first treatments approved for hemophilia that didn't pose the threat of transmitting a blood-borne virus.⁶

A legacy of real patient experience

over
20
years

Over 20 years of treatment experience in the real world.⁷

over
43
billion

ADVATE is a global leader in factor VIII therapy, with over 43 billion International Units distributed globally.*⁸

*As of July 2022.

3
indications

ADVATE is indicated for prophylaxis, on-demand, and surgical use in children and adults.⁷

Interested in ADVATE?

A doctor discussion guide can help you have a productive conversation with your healthcare provider about your treatment options.

Download discussion guide

Committed to advancing hemophilia A care

Since introducing the first recombinant factor VIII treatment, Takeda has made advancements in dosing options, reconstitution with BAXJECT III^®, and the introduction of myPKFiT^® for personalized treatment.^7,8

2003

ADVATE: First recombinant factor VIII (rFVIII) made without added human or animal proteins.^7,8

2006

BAXJECT II^® needleless transfer device.⁸

2007

First rFVIII 3000-IU single-vial dose.⁸

2010

First and only rFVIII 1700-IU single-vial dose.⁸

2011

First and only rFVIII with physical health–related quality-of-life results in the Prescribing Information.⁷

2012

First and only rFVIII 4000-IU single-vial dose and 2-mL diluent option (250 IU, 375 IU, 500 IU, 750 IU, 1000 IU, 1500 IU, and 1700 IU).^7,8

2014

ADVATE with BAXJECT III^® reconstitution system.⁸

2018

myPKFiT for ADVATE receives approval from the FDA for patients 16 and older.⁸

Explore ADVATE
safety information

See safety info

Learn about health-related
quality-of-life data

See results